PetIQ, Inc. (NASDAQ:PETQ) Shares Sold by Nepsis Inc.

Nepsis Inc. trimmed its holdings in shares of PetIQ, Inc. (NASDAQ:PETQ) by 0.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 898,169 shares of the company’s stock after selling 5,609 shares during the period. PetIQ makes up about 4.4% of Nepsis Inc.’s portfolio, making the stock its 12th biggest position. Nepsis Inc. owned about 3.05% of PetIQ worth $16,419,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Los Angeles Capital Management LLC raised its position in PetIQ by 196.6% during the first quarter. Los Angeles Capital Management LLC now owns 129,632 shares of the company’s stock valued at $2,370,000 after acquiring an additional 85,920 shares in the last quarter. Nomura Holdings Inc. increased its holdings in shares of PetIQ by 7.1% during the 4th quarter. Nomura Holdings Inc. now owns 423,496 shares of the company’s stock valued at $8,364,000 after purchasing an additional 28,231 shares in the last quarter. ICA Group Wealth Management LLC acquired a new position in shares of PetIQ in the 4th quarter valued at $35,000. Wellington Management Group LLP purchased a new stake in PetIQ during the fourth quarter worth $1,410,000. Finally, Goldman Sachs Group Inc. grew its position in PetIQ by 11.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,036,292 shares of the company’s stock valued at $20,467,000 after buying an additional 108,870 shares during the period. 94.99% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other PetIQ news, Director Scott Huff sold 12,117 shares of the stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $22.19, for a total value of $268,876.23. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 9.62% of the stock is currently owned by company insiders.

PetIQ Price Performance

NASDAQ:PETQ traded up $0.19 during trading hours on Tuesday, hitting $21.95. 19,703 shares of the stock were exchanged, compared to its average volume of 282,103. The firm’s fifty day moving average price is $19.34 and its 200 day moving average price is $18.50. PetIQ, Inc. has a 52-week low of $14.20 and a 52-week high of $22.98. The company has a market cap of $653.01 million, a P/E ratio of 98.91 and a beta of 1.76. The company has a current ratio of 2.42, a quick ratio of 1.25 and a debt-to-equity ratio of 1.84.

PetIQ (NASDAQ:PETQ) last issued its quarterly earnings results on Wednesday, May 8th. The company reported $0.51 EPS for the quarter, topping the consensus estimate of $0.34 by $0.17. PetIQ had a return on equity of 13.33% and a net margin of 0.66%. The firm had revenue of $308.44 million during the quarter, compared to analysts’ expectations of $302.16 million. As a group, equities research analysts anticipate that PetIQ, Inc. will post 1.09 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on PETQ. Benchmark reiterated a “buy” rating and issued a $30.00 price objective on shares of PetIQ in a research report on Friday, May 10th. Jefferies Financial Group increased their price target on PetIQ from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, March 19th. Four research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $29.00.

PetIQ Company Profile

PetIQ, Inc operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats.